Trend Analysis for Sterile Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Trend Analysis for Sterile Manufacturing
A Pharmaceutical Technology survey examines capacity expansions, outsourcing practices, innovation levels, and the role of quality by design in sterile manufacturing and aseptic processing.

Pharmaceutical Technology

Sterile manufacturing and aseptic processing are important in pharmaceutical manufacturing. To gain a perspective, Pharmaceutical Technology conducted a survey to gauge investments in manufacturing capacity, outsourcing practices, the level of innovation, and the influence of quality by design (QbD). The survey found a fairly strong level of investment in sterile manufacturing and aseptic processing in 2008 and slightly lower levels planned for 2009. Respondents were almost evenly divided in their decision whether to keep manufacturing in house or to outsource and were generally satisfied with the level of innovation in equipment and machinery. And QbD is playing a significant role in companies' sterile-manufacturing practices.

Capacity expansions

Figure 1
More than half, or 58.3%, of respondents said that their companies added capacity for sterile manufacturing or aseptic processing in 2008 (see Figure 1). Almost 40% of respondents said that their companies were planning to add capacity in 2009 or 2010 (see Figure 2).

Figure 2
For those companies that added capacity in 2008, 46% added capacity for finished-product manufacturing. Fifteen percent increased capacity for drug-substance manufacturing, and 39% added capacity in both areas. A similar distribution holds for companies planning to add capacity in 2009 or 2010. Of those companies, 44% plan to add capacity for both drug-substance and finished-product manufacturing. Thirty-nine percent will add capacity for finished-product manufacturing only, and 17% plan to add capacity for drug-substance manufacturing only.

Figure 3
The overwhelming majority of respondents did not have capabilities for sterile manufacturing or aseptic processing for cytotoxic or high-potency products. Approximately 62% of companies responding to the survey did not perform sterile manufacturing or aseptic processing of these products, and 38% did (see Figure 3). Of the companies that did not perform cytotoxic or high-potency manufacturing, only 13% were considering adding this capability.


Figure 4
Respondents were almost evenly divided regarding whether they kept sterile manufacturing or aseptic manufacturing in house or outsourced. Forty-eight percent of respondents said that their companies outsource sterile manufacturing or aseptic processing, and 52% do not outsource (see Figure 4). Of those companies that do outsource, 57% outsource both drug-substance and finished-product manufacturing (see Figure 5). Thirty-three percent outsource manufacturing for finished products only, and 9% outsource only drug-substance manufacturing.

Figure 5
The number one reason for outsourcing is companies believe that it is more cost-effective than producing a product internally. Almost half of all respondents, or 47%, said that outsourcing was more cost-effective than captive production. The other reasons for outsourcing are limited or no internal manufacturing capacity (39% responded thus) and an increase in projects requiring sterile manufacturing (35% responded thus).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here